The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma is a research paper published in Frontiers in Pharmacology (2021). On theSindex it has a DataRank of 0. It has been cited 14 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institutes of Health
Grant: R01CA148706
National Institutes of Health
Grant: 5R01CA148706-10
Targeting the colchicine site in tubulin for advanced melanoma
FWCI
0.67
Citation Percentile
0.7%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals